Dr. Makesha Vernee Miggins, MD

Dr. Miggins practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Miggins' NPI, 1841499456, was assigned on July 13, 2007. Dr. Miggins graduated from Wake Forest School of Medicine in 2007. Dr. Miggins holds Texas license 45173.

Dr. Miggins' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Miggins' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Miggins practices. Vendor and product names are available with a free account.

Surgery is Dr. Miggins' primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Miggins is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Miggins' licenses on file in 10 states: Texas, Florida, Arizona, Georgia, Mississippi, Oklahoma, Tennessee, Alabama, Louisiana and Washington.

Dmand AI lists breast surgery and mastectomy among the conditions Dr. Miggins treats.

CMS data shows 202 Medicare services from Dr. Miggins across 8 procedure codes in 2024, for 88 Medicare patients. Medicare paid $43,882 for them.

CMS counts 88 Medicare patients who saw Dr. Miggins in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 0.96, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Miggins' median patient age at 67, with 100% women.

In 2024, Dr. Miggins wrote 25 Medicare Part D claims for 18 patients. 100% of them were for generic drugs. CMS names the drug for 24 of them, across 2 drugs with 11 or more claims each, at $212 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Miggins for performance year 2024, reported as part of a group. Dr. Miggins accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 25 procedures of mastectomy by Dr. Miggins, more than 83% of the clinicians it reports for that procedure.

Dmand AI links 8 papers to Dr. Miggins, published from 2011 to 2020. The most frequent topics are Breast Neoplasms, Antineoplastic Agents and Axilla. Dr. Miggins' most frequent co-authors are Darwin Noel Ang, MD, Philip A. Efron, MD and Azra Bihorac, MD.

Dmand AI links Dr. Miggins to 1 clinical trial. Conditions studied include Triple Negative Breast Neoplasms and Breast Neoplasms.

CMS Open Payments shows 4 general payments to Dr. Miggins from 4 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $132.

Dr. Miggins graduated from Wake Forest School of Medicine in 2007.

Dr. Miggins is in network with 4 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 3. Check the plan with the practice before a visit.